Dr. Boudjadi's current research focuses on the use of antibody-drug conjugates (ADC) in bladder cancer (urothelial carcinoma). He is working on developing and characterizing novel in vivo and in vitro models of ADC resistance. He uses multidisciplinary approaches involving genomics, bioinformatics, cell culture, and animal models to determine the biological relevance of the mechanisms of ADC resistance.

Dr. Boudjadi is also working on discovering new therapy targets for rare genitourinary tumors (GU). Although these tumors are rare, they account for about 20% of all malignancies when considered cumulatively. The incidence of these tumors is increasing by 0.5% each year. These tumors are generally aggressive and have a high rate of relapse. They are also resistant to conventional therapies and their biology is not yet fully understood. Moreover, there are no efficient targeted therapies available for most of these tumors. Dr. Boudjadi's research aims to explore the DNA changes, expression signatures and pathway alterations to better understand the biology of these aggressive rare tumors and discover new oncogenic drivers and potential therapeutic targets.